GLYC: GlycoMimetics, Inc. Net earnings per share for the last 12 months

Symbol and logo of brand GlycoMimetics Inc. (GLYC)

GlycoMimetics, Inc. (GLYC) develops targeted carbohydrate mimetics to combat leukemia, relying heavily on patents and FDA verdicts. The EPS trend over the last 12 months illustrates this volatility, where the value -0.46 represents the current figure. A lack of revenue and trial uncertainty leave the company vulnerable, while its environmental strategy is limited solely to the proper disposal of laboratory waste.

GLYC (GlycoMimetics, Inc.) Net earnings per share (EPS TTM) history from 07/04/2022 to 06/16/2025

Analytical breakdowns for GlycoMimetics, Inc.

- share price and expert price forecast:
Stock Quotes GlycoMimetics Corp|GLYC - Fair Value Consensus
- market capitalization information:
Market Valuation GlycoMimetics, Inc.|GLYC - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share GlycoMimetics|GLYC - Book Capitalization|Market Value to Book Value Ratio glycomimetics.com|GLYC - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital GlycoMimetics, Inc.|GLYC - Long-Term Indebtedness to Equity|Short-Term Debt to Capital GlycoMimetics Corp|GLYC - Company Cumulative Debt|Debt to Book Value GlycoMimetics, Inc.|GLYC - Amount of Long-Term Liabilities|Company Short-Term Debts GlycoMimetics|Quick Ratio glycomimetics.com
- net income and valuation multiples indicators:
GLYC - Company Profit|Future Profit GlycoMimetics, Inc.|GLYC - Company Value to Net Income|Projected Price to Earnings GlycoMimetics Corp|GLYC - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple GlycoMimetics, Inc.|GLYC - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) GlycoMimetics|GLYC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months glycomimetics.com|GLYC - Earnings per share increase in current year|Earnings growth forecast for next year GlycoMimetics, Inc.
- sales and revenue data:
GLYC - Revenue and Sales Volume|Company Projected Revenue GlycoMimetics Corp|GLYC - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple GlycoMimetics, Inc.
Basic company analysis:glycomimetics.com - GLYC
Manufactured products of GlycoMimetics Inc.

Asset quality is assessed through the actual yield of each share. This metric calculates the total annual net income divided by the total number of securities. By analyzing the TTM fundamental earnings per share trend, an investor identifies hidden financial risks. For GlycoMimetics, Inc. (GLYC), this indicator reflects the cost efficiency of developing oncology drugs. Scientific synergy with medical centers should convert into growth for this metric.

Who GlycoMimetics, Inc. competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (exelixis.com)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Bio) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Enliven Corp|Earnings per share for the last twelve months ORIC Pharmaceuticals (ORIC)|RLAY (relaytx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics, Inc.)|Net earnings per share for the trailing year Tyra Biosciences Inc|Verastem Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Corp|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (C4 Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics, Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc - Earnings per share for the last 12 months|Karyopharm Therapeutics Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|Aadi Bioscience - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corporation - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics) - Net earnings per share (EPS TTM)